General Info

CytRx Corporation is a biopharmaceutical company engaged in the development of high-value therapeutics utilizing its core technologies in small molecule drugs, RNAi drug discovery and DNA vaccines. RNAi has been shown to effectively silence a targeted disease-causing gene within a living cell. The technology uses ribonucleic acid to selectively turn off the harmful genes of infectious viruses or malignant tumor cells. The company s small molecule drug candidates provide cellular protection by activating molecular chaperone proteins that can repair or degrade proteins that are believed to cause many diseases. The company s research and development activities are focused on two of its technologies, FLOCOR, an intravenous agent for acute vaso-occlusive disorders and related acute care applications, and TRAXZFECT, a DNA delivery technology which may have wide applications in DNA vaccines and gene therapy. CytRx Corporation is headquartered in Los Angeles.